Phase 2 Clinical Trial of EDP1815 in Atopic Dermatitis
On December 22, 2021, the Company announced planned updates to the study protocol for its Phase 2 clinical trial of EDP1815 in atopic dermatitis. Based on
Decentralized autonomous organization VitaDAO, which provides funding for longevity science research, has concluded a successful funding round, raising $4.1 million.